ArticleFrontiers in medicine2026
Serum omentin and chemerin levels in patients with coronavirus disease 2019.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemerin and omentin are adipokines secreted mainly by visceral adipose tissue, with pro- and anti-inflammatory properties, respectively. Their role in coronavirus disease 2019 (COVID-19) remains incompletely understood and available data are inconsistent. Methods: This single-center case-control study included 40 hospitalized patients with COVID-19 and 24 non-COVID controls. Serum samples were collected in COVID-19 patients on admission (Day 0) and on Day 7 of hospitalization, and once in controls. Concentrations of omentin and chemerin and routine laboratory parameters were measured using enzyme immunoassays. Results: Compared with controls, patients with COVID-19 had higher inflammatory markers, including C-reactive protein, ferritin, interleukin-6 and D-dimer. Baseline serum omentin concentrations did not differ between COVID-19 patients and controls (363.6 [245.2-513.0] vs. 368.9 [254.1-468.8] ng/mL; Conclusion: In this cohort of hospitalized but predominantly non-critically ill patients, COVID-19 was associated with sustained elevation of circulating chemerin but not with alterations in omentin levels. Our findings are consistent with a potential role for chemerin, but not omentin, in the systemic inflammatory response to SARS-CoV-2 infection and complement previous reports describing divergent adipokine profiles in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.